Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $21.44, for a total value of $142,940.48. Following the completion of the sale, the chief operating officer now owns 323,310 shares in the company, valued at approximately $6,931,766.40. This represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Anish Patel also recently made the following trade(s):

• On Friday, February 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.93, for a total value of $146,207.31.
• On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.18, for a total value of $524,706.00.

Enliven Therapeutics Price Performance

ELVN opened at $20.69 on Wednesday. Enliven Therapeutics, Inc. has a one year low of $10.90 and a one year high of $30.03. The company’s 50 day simple moving average is $21.76 and its 200-day simple moving average is $23.86. The stock has a market capitalization of $1.01 billion, a P/E ratio of -10.89 and a beta of 1.04.

Analysts Set New Price Targets

ELVN has been the subject of a number of research analyst reports. Robert W. Baird lifted their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, November 15th. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $38.25.

Institutional Trading of Enliven Therapeutics

Several hedge funds have recently modified their holdings of ELVN. Tower Research Capital LLC TRC grew its stake in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Enliven Therapeutics during the fourth quarter valued at approximately $97,000. BNP Paribas Financial Markets bought a new stake in shares of Enliven Therapeutics during the fourth quarter valued at approximately $112,000. ExodusPoint Capital Management LP bought a new stake in shares of Enliven Therapeutics during the fourth quarter valued at approximately $200,000. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Enliven Therapeutics during the fourth quarter worth approximately $228,000. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.